eligibility_summary
Eligible: adults 18–75 with KPS ≥50 and recurrent/progressive WHO grade 4 glioma after standard therapy, IL13Rα2-positive tumor, PBMC collection feasible, adequate labs/organ function, agree to effective contraception. Exclude: pregnancy/breastfeeding, bevacizumab contraindication, systemic steroids >10 mg prednisone eq within 5 days pre-infusion, other uncontrolled cancer, active HIV/HBV/HCV/TB, autoimmune or severe psychiatric disease, prior cell therapy, other concerns.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: IL13Rα2 CAR‑T, an autologous chimeric antigen receptor T‑cell therapy. Mechanism: Patient T cells are engineered to express a CAR that binds IL13Rα2 (a high‑affinity IL‑13 receptor subunit overexpressed in glioma). Antigen engagement triggers CAR signaling (CD3ζ with costimulatory domains), activating T cells to kill IL13Rα2+ tumor cells and secrete effector cytokines. Delivery: Intraventricular infusions via Ommaya reservoir every 2 weeks. Targets: IL13Rα2 on WHO grade 4 glioma cells, leverages the IL‑13/IL13Rα2 axis. Effector cells/pathways: CD3+ T lymphocytes, CAR/TCR activation, cytotoxicity, and immune-mediated tumor lysis. Purpose: Phase 1 dose exploration for safety, MTD/RP2D, and preliminary efficacy in r/r glioma.